Sign in
CompletedPhase 1

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Key facts

Who runs it
Sanofi Pasteur, a Sanofi Company
Where
Australia and United Kingdom8 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
159 people enrolled
Started
12 Apr 2023
Ended
14 Mar 2024
Type of study
Interventional, 6 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • H3 mRNA / LNP Vaccine
  • Quadrivalent recombinant influenza Vaccine (RIV4)
Record updated
12 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Aged 18 years and above on the day of inclusion; *Aged 18 years to 49 years or 60 years and above on the day of inclusion (substudy 01)
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:; Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile; OR
  • Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration
  • A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) at the screening visit
  • Inclusion Criteria to be Checked at Visit 1 (Day 1); Participants are eligible for the study only if all of the following criteria are met:; A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
  • Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile; OR
  • Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration; A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the first dose of study intervention

Who cannot take part

  • Previous vaccination against influenza in the previous 6 months with an investigational or marketed vaccine
  • Previous history of myocarditis, pericarditis, and/or myopericarditis
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
  • Receipt of any vaccine in the 4 weeks preceding study enrollment or planned receipt of any vaccine in the 4 weeks following study intervention administration
  • Receipt of any mRNA vaccine/product in the 2 months preceding study enrollment or planned receipt of any mRNA vaccine/product within the 2 months following study intervention administration
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months -Participation at the time of study enrollment (or in the 4 weeks preceding study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
  • Previous vaccination against influenza in the previous 6 months with an investigational or marketed vaccine
  • Positive test for human immunodeficiency virus (HIV) antigen and/or antibodies (Abs), hepatitis B (HB) virus surface antigen (HBsAg), hepatitis B core antibodies (HBcAb), or hepatitis C virus antibodies (HCV Abs)
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol [PEG], polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA COVID-19 vaccine
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on Investigator's judgment
  • Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion
  • Exclusion criteria to be checked at Visit 1 Day 1:; Moderate or severe acute illness/infection (according to Investigator's judgment) or febrile illness (temperature ≥ 38.0°C [100.4°F]) on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided; The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
  • Any screening laboratory parameter with laboratory abnormalities that are greater than Grade 1 or deemed clinically significant in the opinion of the Investigator; OR, any screening Liver Function Test (ALT, AST, Bilirubin) > 1.2x Upper Limit of Normal or any other screening laboratory parameter outside of the range of normal limits for age and gender
  • Screening electrocardiogram (ECG) or troponin value that is consistent with probable or possible myocarditis, pericarditis, and/or myopericarditis or screening ECG that demonstrates clinically relevant abnormalities that may affect participant safety or study results
  • Self-reported thrombocytopenia, contraindicating intramuscular vaccination based on Investigator's judgment

Where is this trial?

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a Phase 1, parallel, randomized, active-controlled, multi-center, dose-esclation study with a Master Protocol design which will include several substudies that are developed to evaluate the safety and immunogenicity of different dose levels of modified messenger ribonucleic acid (mRNA) vaccines encoding full length hemagglutinin (HA) sequence of influenza virus encapsulated in lipid nanoparticles (LNPs) (hereafter referred to as HA mRNA vaccines) compared to control(s). The HA mRNA vaccine candidates and control(s) are presented in the substudy protocols.

Read full original descriptionShow less

The aim is to generate clinical data across different substudies to provide learnings regarding the mRNA technology to support optimization of the mRNA platform including mRNA and LNP design and to support the decision of LNP and dose selection for future projects using mRNA technology.

The purpose of this Substudy 01 is to evaluate the safety and immunogenicity of a single IM injection of up to 5 dose levels of a monovalent modified mRNA encoding the full-length HA sequence of A/Tasmania/503/2020 (H3N2) influenza virus encapsulated in LNP (hereafter referred to as H3 mRNA /LNP) administered as a single intramuscular (IM) injection in adults 18 to 49 years of age and 60 years of age and above, compared to the following active control: a quadrivalent recombinant influenza vaccine (RIV4).

The 6 groups in the trial

  • Group 1: H3 mRNA /LNP dose 1Treatment being tested

    Participants will receive one intramuscular (IM) dose of H3 mRNA/LNP at Day 01

    Treatment: H3 mRNA / LNP Vaccine

  • Group 2: H3 mRNA /LNP dose 2Treatment being tested

    Participants will receive one IM dose of H3 mRNA/LNP at Day 01

    Treatment: H3 mRNA / LNP Vaccine

  • Group 3: H3 mRNA /LNP dose 3Treatment being tested

    Participants will receive one IM dose of H3 mRNA/LNP at Day 01

    Treatment: H3 mRNA / LNP Vaccine

  • Group 4: H3 mRNA /LNP dose 4Treatment being tested

    Participants will receive one IM dose of H3 mRNA/LNP at Day 01

    Treatment: H3 mRNA / LNP Vaccine

  • Group 5: H3 mRNA /LNP dose 5Treatment being tested

    Participants will receive one IM dose of H3 mRNA/LNP at Day 01

    Treatment: H3 mRNA / LNP Vaccine

  • Group 6 (Control Group): RIV4 doseExisting treatment, for comparison

    Participants will receive one IM dose of RIV4 at Day 01

    Treatment: Quadrivalent recombinant influenza Vaccine (RIV4)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I, Parallel, Randomized, Active-controlled, Multi-center, Dose-escalation Study With Early Safety Data Reviews to Assess Safety and Immunogenicity of One Monovalent Modified Influenza mRNA Vaccine Encapsulated in LNP, in Adults Aged 18 to 49 Years and 60 Years and Above.
Record updated
12 September 2025